



Complete Summary

TITLE

Hematology: percentage of patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission, who were prescribed or received intravenous bisphosphonate therapy within the 12 month reporting period.

SOURCE(S)

American Society of Hematology, Physician Consortium for Performance Improvement®. Hematology physician performance measurement set. Chicago (IL): American Medical Association (AMA); 2007 Jan. 22 p. [10 references]

Measure Domain

PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the [Measure Validity](#) page.

SECONDARY MEASURE DOMAIN

Does not apply to this measure

Brief Abstract

DESCRIPTION

This measure is used to assess the percentage of patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission, who were prescribed or received intravenous bisphosphonate therapy within the 12 month reporting period.

RATIONALE

Multiple myeloma (MM) is a disease characterized by bone destruction, in the form of diffuse osteopenia and/or osteolytic lesions, which develop in 85% of patients. Bisphosphonates can inhibit bone resorption by reducing the number and activity of osteoclasts and therefore could "reduce pain and bone fractures in people with multiple myeloma".*

*The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines and represent the evidence base for the measure:

Based on published data and clinical experience, the guidelines recommend the use of bisphosphonates for all patients with multiple myeloma who have bone disease, including osteopenia. In 10% to 20% of patients with earlier-stage disease who do not have bone disease, bisphosphonates may be considered but preferably in a clinical trial. (National Comprehensive Cancer Network [NCCN])

Intravenous bisphosphonates should be administered monthly for patients with MM and lytic disease evident on plain radiographs. It is reasonable to start intravenous bisphosphonates in patients with MM who do not have lytic bone disease if there is evidence of osteopenia or osteoporosis on bone mineral density studies. No randomized clinical trials support the use of bisphosphonates in patients with smoldering MM. We believe that bisphosphonates should be used only in the setting of a clinical trial [in these patients]. (Mayo Clinic)

PRIMARY CLINICAL COMPONENT

Multiple myeloma; bisphosphonates therapy

DENOMINATOR DESCRIPTION

All patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

NUMERATOR DESCRIPTION

Patients who were prescribed or received intravenous bisphosphonate therapy* within the 12 month reporting period

*For the purpose of this measure, bisphosphonate therapy includes the following medications: pamidronate and zoledronate.

Evidence Supporting the Measure

EVIDENCE SUPPORTING THE CRITERION OF QUALITY

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence
- A systematic review of the clinical literature

Evidence Supporting Need for the Measure

NEED FOR THE MEASURE

Unspecified

State of Use of the Measure

STATE OF USE

Current routine use

CURRENT USE

Internal quality improvement
National reporting

Application of Measure in its Current Use**CARE SETTING**

Ambulatory Care
Physician Group Practices/Clinics

PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Advanced Practice Nurses
Physician Assistants
Physicians

LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Individual Clinicians

TARGET POPULATION AGE

Age greater than or equal to 18 years

TARGET POPULATION GENDER

Either male or female

STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

Characteristics of the Primary Clinical Component**INCIDENCE/PREVALENCE**

Unspecified

ASSOCIATION WITH VULNERABLE POPULATIONS

Unspecified

BURDEN OF ILLNESS

Unspecified

UTILIZATION

Unspecified

COSTS

Unspecified

Institute of Medicine National Healthcare Quality Report Categories

IOM CARE NEED

Living with Illness

IOM DOMAIN

Effectiveness

Data Collection for the Measure

CASE FINDING

Users of care only

DESCRIPTION OF CASE FINDING

All patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission

DENOMINATOR SAMPLING FRAME

Patients associated with provider

DENOMINATOR INCLUSIONS/EXCLUSIONS

Inclusions

All patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission

Exclusions

- Documentation of medical reason(s) for not prescribing bisphosphonates (e.g., patients who do not have bone disease, patients with dental disease, patients with renal insufficiency)
- Documentation of patient reason(s) for not prescribing bisphosphonates

RELATIONSHIP OF DENOMINATOR TO NUMERATOR

All cases in the denominator are equally eligible to appear in the numerator

DENOMINATOR (INDEX) EVENT

Clinical Condition

DENOMINATOR TIME WINDOW

Time window is a single point in time

NUMERATOR INCLUSIONS/EXCLUSIONS

Inclusions

Patients who were prescribed or received intravenous bisphosphonate therapy* within the 12 month reporting period

*For the purpose of this measure, bisphosphonate therapy includes the following medications: pamidronate and zoledronate.

Exclusions

None

MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

NUMERATOR TIME WINDOW

Fixed time period

DATA SOURCE

Administrative data
Medical record

LEVEL OF DETERMINATION OF QUALITY

Individual Case

PRE-EXISTING INSTRUMENT USED

Unspecified

Computation of the Measure

SCORING

Rate

INTERPRETATION OF SCORE

Better quality is associated with a higher score

ALLOWANCE FOR PATIENT FACTORS

Unspecified

STANDARD OF COMPARISON

Internal time comparison

Evaluation of Measure Properties

EXTENT OF MEASURE TESTING

Unspecified

Identifying Information

ORIGINAL TITLE

Measure #3: multiple myeloma - treatment with bisphosphonates.

MEASURE COLLECTION

[The Physician Consortium for Performance Improvement® Measurement Sets](#)

MEASURE SET NAME

[Hematology Physician Performance Measurement Set](#)

SUBMITTER

American Medical Association on behalf of the American Society of Hematology and the Physician Consortium for Performance Improvement®

DEVELOPER

American Society of Hematology
Physician Consortium for Performance Improvement®

FUNDING SOURCE(S)

Unspecified

COMPOSITION OF THE GROUP THAT DEVELOPED THE MEASURE

Steven L. Allen, MD (*Co-Chair*); William E. Golden, MD (*Co-Chair*); Kenneth Adler, MD; Daniel Halevy, MD; Stuart Henochowicz, MD, MBA; Timothy Miley, MD; David

Morris, MD; John M. Rainey, MD; Samuel M. Silver, MD, PhD; Lawrence Solberg, Jr., MD, PhD

Mila Becker, Esq., American Society of Hematology; Pamela Ferraro, MS, American Society of Hematology; Sue Frechette, BSN, MBA (Consultant), American Society of Hematology

Karen S. Kmetik, PhD, American Medical Association; Samantha Tierney, MPH, American Medical Association

Kristen McNiff, MPH, American Society of Clinical Oncology

Emily Wilson, American Society for Therapeutic Radiology and Oncology

Hildy Dillon, MPH, Leukemia and Lymphoma Society; Mary Grace Pagaduan, MPH, Leukemia and Lymphoma Society

Sue Nedza, MD, MBA, FACEP, Centers for Medicare & Medicaid Services; Sylvia Publ, MBA, RHIA, Centers for Medicare & Medicaid Services

Rebecca Kresowik, Consortium Consultant; Timothy F. Kresowik, MD, Consortium Consultant

FINANCIAL DISCLOSURES/OTHER POTENTIAL CONFLICTS OF INTEREST

Conflicts, if any, are disclosed in accordance with the Physician Consortium for Performance Improvement® conflict of interest policy.

ENDORSER

National Quality Forum

INCLUDED IN

Ambulatory Care Quality Alliance
Physician Quality Reporting Initiative

ADAPTATION

Measure was not adapted from another source.

RELEASE DATE

2007 Jan

MEASURE STATUS

This is the current release of the measure.

SOURCE(S)

American Society of Hematology, Physician Consortium for Performance Improvement®. Hematology physician performance measurement set. Chicago (IL): American Medical Association (AMA); 2007 Jan. 22 p. [10 references]

MEASURE AVAILABILITY

The individual measure, "Measure #3: Multiple Myeloma - Treatment with Bisphosphonates," is published in the "Hematology Physician Performance Measurement Set." This document and technical specifications are available in Portable Document Format (PDF) from the American Medical Association (AMA)-convened Physician Consortium for Performance Improvement® Web site: www.physicianconsortium.org.

For further information, please contact AMA staff by e-mail at cqi@ama-assn.org.

NQMC STATUS

This NQMC summary was completed by ECRI Institute on September 13, 2007. The information was verified by the measure developer on October 26, 2007.

COPYRIGHT STATEMENT

© Copyright 2006-7 American Medical Association and American Society of Hematology. All Rights Reserved.

Disclaimer

NQMC DISCLAIMER

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at <http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx>.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

© 2008 National Quality Measures Clearinghouse

Date Modified: 10/27/2008

